Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):959-964. doi: 10.1016/j.ijrobp.2017.12.012. Epub 2017 Dec 23.
To evaluate the efficacy and toxicity of external beam reirradiation using a pulsed low-dose-rate (PLDR) technique.
We evaluated patients treated with PLDR reirradiation from 2009 to 2016 at a single institution. Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 4.0, and local control was assessed using the Response Evaluation Criteria In Solid Tumors, version 1.1. On univariate analysis (UVA), the χ and Fisher exact tests were used to assess the toxicity outcomes. Competing risk analysis using cumulative incidence function estimates were used to assess local progression.
A total of 39 patients were treated to 41 disease sites with PLDR reirradiation. These patients had a median follow-up time of 8.8 months (range 0.5-64.7). The targets were the thorax, abdomen, and pelvis, including 36 symptomatic sites. The median interval from the first radiation course and reirradiation was 26.2 months; the median dose of the first and second course of radiation was 50.4 Gy and 50 Gy, respectively. Five patients (13%) received concurrent systemic therapy. Of the 39 patients, 9 (23%) developed grade ≥2 acute toxicity, most commonly radiation dermatitis (5 of 9). None developed grade ≥4 acute or subacute toxicity. The only grade ≥2 late toxicity was late skin toxicity in 1 patient. On UVA, toxicity was not significantly associated with the dose of the first course of radiation or reirradiation, the interval to reirradiation, or the reirradiation site. Of the 41 disease sites treated with PLDR reirradiation, 32 had pre- and post-PLDR scans to evaluate for local control. The local progression rate was 16.5% at 6 months and 23.8% at 12 months and was not associated with the dose of reirradiation, the reirradiation site, or concurrent systemic therapy on UVA. Of the 36 symptomatic disease sites, 25 sites (69%) achieved a symptomatic response after PLDR, including 6 (17%) with complete symptomatic relief.
Reirradiation with PLDR is effective and well-tolerated. The risk of late toxicity and the durability of local control were limited by the relatively short follow-up duration in the present cohort.
评估使用脉冲低剂量率(PLDR)技术进行外照射再放疗的疗效和毒性。
我们在一个机构评估了 2009 年至 2016 年接受 PLDR 再放疗的患者。使用通用不良事件术语标准 4.0 对毒性进行分级,并使用实体瘤反应评估标准 1.1 评估局部控制情况。在单变量分析(UVA)中,使用 χ 和 Fisher 精确检验来评估毒性结果。使用累积发生率函数估计的竞争风险分析用于评估局部进展情况。
共 39 例患者在 41 个疾病部位接受 PLDR 再放疗。这些患者的中位随访时间为 8.8 个月(范围 0.5-64.7)。靶区包括胸部、腹部和骨盆,其中 36 个为症状性部位。从第一次放射治疗到再放疗的中位间隔时间为 26.2 个月;第一次和第二次放射治疗的中位剂量分别为 50.4Gy 和 50Gy。5 例(13%)患者同时接受系统治疗。39 例患者中,9 例(23%)发生≥2 级急性毒性,最常见的是放射性皮炎(9 例中的 5 例)。无≥4 级急性或亚急性毒性。唯一≥2 级晚期毒性是 1 例晚期皮肤毒性。在 UVA 中,毒性与第一次放射治疗或再放疗的剂量、再放疗的间隔时间或再放疗部位均无显著相关性。在接受 PLDR 再放疗的 41 个疾病部位中,有 32 个部位在接受 PLDR 前后进行了扫描以评估局部控制情况。6 个月时局部进展率为 16.5%,12 个月时为 23.8%,在 UVA 中与再放疗剂量、再放疗部位或同时进行的系统治疗均无相关性。在 36 个有症状的疾病部位中,25 个部位(69%)在 PLDR 后获得了症状缓解,其中 6 个部位(17%)完全缓解了症状。
PLDR 再放疗有效且耐受良好。在本队列中,由于随访时间相对较短,晚期毒性风险和局部控制的持久性受到限制。